Clinical Microbiology and Antimicrobial Chemotherapy. 2012; 14(3):222-234
Invasive fungal infections are an actual problem of the modern medicine. This is due to the widening population of the affected patients and the increasing number of fungal strains that are resistant to the previously extensively used antifungal preparations. Candida spp. is the most frequent causative agents of invasive fungal infections. The emergence of echinocandins class was a breakthrough in the antifungal therapy because of their high activity against Candida spp. and some other pathogens, as well as their favorable safety profile. The recent IDSA and ESCMID recommendations in the treatment of Candida infections are strictly underline the necessity of the echinocandins administration in the majority of moderate and severe forms of Candida infections, also in patients with a history of the previous therapy with azoles. Anidulafungin after caspofungin and micafungin is a last of the registered in the market echinocandins representative, which possess good safety and tolerability profile, also a good efficacy in the therapy of invasive and esophageal candidiasis. The absence of clinically significant drugs interactions is especially important in patients with concomitant therapy, also in patients with renal or hepatic impairment as long as there are no requirements of anidulafungin dose adjustment in such categories of patients.